Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Phase 2

Completed

Conditions: Untreated Childhood Rhabdomyosarcoma
Childhood Alveolar Rhabdomyosarcoma
Childhood Embryonal Rhabdomyosarcoma
Adult Rhabdomyosarcoma
Metastatic Childhood Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Biological: Cixutumumab
Biological: Dactinomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Doxorubicin Hydrochloride
Drug: Ifosfamide
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Temozolomide
Drug: Vincristine Sulfate Liposome

First Posted Date: 2010-01-25

Last Posted Date: 2017-08-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 175

Registration Number: NCT01055314

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States

and more 136 locations

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2009-12-18

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 74

Registration Number: NCT01035463

Locations: 🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Phase 2

Terminated

Conditions: Recurrent or Refractory Pediatric Ependymoma

Interventions: Drug: erlotinib
Drug: etoposide

First Posted Date: 2009-12-15

Last Posted Date: 2024-12-12

Lead Sponsor: OSI Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT01032070

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology, Boston, Massachusetts, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 25 locations

IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Plerixafor
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2009-12-09

Last Posted Date: 2015-01-26

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 6

Registration Number: NCT01027923

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Phase 3

Terminated

Conditions: Choroid Plexus Tumors
Brain Cancer

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Etoposide
Drug: Vincristine
Drug: Dactinomycin
Drug: Leucovorin
Drug: Irinotecan
Drug: Doxorubicin
Drug: Methotrexate
Drug: Temozolomide

First Posted Date: 2009-11-17

Last Posted Date: 2019-08-20

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 27

Registration Number: NCT01014767

Locations: 🇳🇿
Christchurch Hospital, Christchurch, New Zealand
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇭🇺
Semmelweis University, Budapest, Hungary

and more 2 locations

Merkel Positron Emission Tomography (PET) Protocol

Phase 2

Completed

Conditions: Merkel Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Radiation: Radiotherapy

First Posted Date: 2009-11-16

Last Posted Date: 2022-11-18

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 43

Registration Number: NCT01013779

Locations: 🇦🇺
Royal Prince Alfred, Sydney, New South Wales, Australia
🇦🇺
Royal Brisbane Hospital, Herston, Queensland, Australia
🇦🇺
Sir Charles Gairdner, Nedlands, Western Australia, Australia

and more 10 locations

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Childhood Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Plasma Cell Leukemia
Progression of Multiple Myeloma or Plasma Cell Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Childhood Hodgkin Lymphoma
t(14;16)

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-11-05

Last Posted Date: 2019-06-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01008462

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Phase 1

Completed

Conditions: Leukemia-Lymphoma, Adult T-Cell

Interventions: Drug: Bortezomib
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Raltegravir

First Posted Date: 2009-10-23

Last Posted Date: 2017-03-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT01000285

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Miami Hospital/Sylvester, Miami, Florida, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 3 locations

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma
B-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Rituximab
Drug: Vorinostat

First Posted Date: 2009-10-09

Last Posted Date: 2020-03-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00992446

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Procedure: Surgery
Radiation: Chest Irradiation
Drug: Cisplatin
Drug: Etoposide
Radiation: Prophylactic Cranial Irradiation

First Posted Date: 2009-09-25

Last Posted Date: 2016-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00984997

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy